Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Predictors of progression in systemic sclerosis patients with interstitial lung disease.

Distler O, Assassi S, Cottin V, Cutolo M, Danoff SK, Denton CP, Distler JHW, Hoffmann-Vold AM, Johnson SR, Müller Ladner U, Smith V, Volkmann ER, Maher TM.

Eur Respir J. 2020 Feb 20. pii: 1902026. doi: 10.1183/13993003.02026-2019. [Epub ahead of print] Review.

PMID:
32079645
2.

Acute exacerbation of idiopathic pulmonary fibrosis: International survey and call for harmonisation.

Kreuter M, Polke M, Walsh SLF, Krisam J, Collard HR, Chaudhuri N, Avdeev S, Behr J, Calligaro G, Corte T, Flaherty K, Funke-Chambour M, Kolb M, Kondoh Y, Maher TM, Molina MM, Morais A, Moor CC, Morisset J, Pereira C, Quadrelli S, Selman M, Tzouvelekis A, Valenzuela C, Vancheri C, Vicens-Zygmunt V, Wälscher J, Wuyts W, Wijsenbeek M, Cottin V, Bendstrup E.

Eur Respir J. 2020 Feb 14. pii: 1901760. doi: 10.1183/13993003.01760-2019. [Epub ahead of print]

PMID:
32060068
3.

Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials.

Kreuter M, Wuyts WA, Wijsenbeek M, Bajwah S, Maher TM, Stowasser S, Male N, Stansen W, Schoof N, Orsatti L, Swigris J.

Respir Res. 2020 Jan 30;21(1):36. doi: 10.1186/s12931-020-1298-1.

4.

Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and is independent of radiological disease extent.

Invernizzi R, Barnett J, Rawal B, Nair A, Ghai P, Kingston S, Chua F, Wu Z, Wells AU, Renzoni ER, Nicholson AG, Rice A, Lloyd CM, Byrne AJ, Maher TM, Devaraj A, Molyneaux PL.

Eur Respir J. 2020 Jan 24. pii: 1901519. doi: 10.1183/13993003.01519-2019. [Epub ahead of print]

PMID:
31980496
5.

Treatment of Acute Exacerbation of IPF - A Call to Arms.

Kreuter M, Maher TM.

Am J Respir Crit Care Med. 2020 Jan 24. doi: 10.1164/rccm.202001-0057ED. [Epub ahead of print] No abstract available.

PMID:
31978310
6.

Dynamics of human monocytes and airway macrophages during healthy aging and after transplant.

Byrne AJ, Powell JE, O'Sullivan BJ, Ogger PP, Hoffland A, Cook J, Bonner KL, Hewitt RJ, Wolf S, Ghai P, Walker SA, Lukowski SW, Molyneaux PL, Saglani S, Chambers DC, Maher TM, Lloyd CM.

J Exp Med. 2020 Mar 2;217(3). pii: e20191236. doi: 10.1084/jem.20191236.

PMID:
31917836
7.

Defining genetic risk factors for scleroderma-associated interstitial lung disease : IRF5 and STAT4 gene variants are associated with scleroderma while STAT4 is protective against scleroderma-associated interstitial lung disease.

Stock CJW, De Lauretis A, Visca D, Daccord C, Kokosi M, Kouranos V, Margaritopoulos G, George PM, Molyneaux PL, Nihtyanova S, Chua F, Maher TM, Ong V, Abraham DJ, Denton CP, Wells AU, Wain LV, Renzoni EA.

Clin Rheumatol. 2020 Jan 8. doi: 10.1007/s10067-019-04922-6. [Epub ahead of print]

PMID:
31916109
8.

Clinical quantification of the integrin αvβ6 by [18F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study).

Lukey PT, Coello C, Gunn R, Parker C, Wilson FJ, Saleem A, Garman N, Costa M, Kendrick S, Onega M, Kang'ombe AR, Listanco A, Davies J, Ramada-Magalhaes J, Moz S, Fahy WA, Maher TM, Jenkins G, Passchier J, Marshall RP.

Eur J Nucl Med Mol Imaging. 2019 Dec 9. doi: 10.1007/s00259-019-04586-z. [Epub ahead of print]

PMID:
31814068
9.

The Role of the Lung's Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis.

Spagnolo P, Molyneaux PL, Bernardinello N, Cocconcelli E, Biondini D, Fracasso F, Tiné M, Saetta M, Maher TM, Balestro E.

Int J Mol Sci. 2019 Nov 10;20(22). pii: E5618. doi: 10.3390/ijms20225618. Review.

10.

Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis.

Allen RJ, Guillen-Guio B, Oldham JM, Ma SF, Dressen A, Paynton ML, Kraven LM, Obeidat M, Li X, Ng M, Braybrooke R, Molina-Molina M, Hobbs BD, Putman RK, Sakornsakolpat P, Booth HL, Fahy WA, Hart SP, Hill MR, Hirani N, Hubbard RB, McAnulty RJ, Millar AB, Navaratnam V, Oballa E, Parfrey H, Saini G, Whyte MKB, Zhang Y, Kaminski N, Adegunsoye A, Strek ME, Neighbors M, Sheng XR, Gudmundsson G, Gudnason V, Hatabu H, Lederer DJ, Manichaikul A, Newell JD Jr, O'Connor GT, Ortega VE, Xu H, Fingerlin TE, Bossé Y, Hao K, Joubert P, Nickle DC, Sin DD, Timens W, Furniss D, Morris AP, Zondervan K, Hall IP, Sayers I, Tobin MD, Maher TM, Cho MH, Hunninghake GM, Schwartz DA, Yaspan BL, Molyneaux PL, Flores C, Noth I, Jenkins RG, Wain LV.

Am J Respir Crit Care Med. 2019 Nov 11. doi: 10.1164/rccm.201905-1017OC. [Epub ahead of print]

PMID:
31710517
11.

Cost-effectiveness of ambulatory oxygen in improving quality of life in fibrotic lung disease: preliminary evidence from the AmbOx Trial.

Whitty JA, Rankin J, Visca D, Tsipouri V, Mori L, Spencer L, Adamali H, Maher TM, Hopkinson NS, Birring SS, Farquhar M, Wells AU, Sestini P, Renzoni EA.

Eur Respir J. 2020 Feb 6;55(2). pii: 1901157. doi: 10.1183/13993003.01157-2019. Print 2020 Feb. No abstract available.

PMID:
31699838
12.

Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease.

Alfieri V, Crisafulli E, Visca D, Chong WH, Stock C, Mori L, de Lauretis A, Tsipouri V, Chua F, Kouranos V, Kokosi M, Hogben C, Molyneaux PL, George PM, Maher TM, Chetta AA, Sestini P, Wells AU, Renzoni EA.

Eur Respir J. 2020 Feb 20;55(2). pii: 1901681. doi: 10.1183/13993003.01681-2019. Print 2020 Feb. No abstract available.

PMID:
31699833
13.

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. Reply.

Distler O, Gahlemann M, Maher TM.

N Engl J Med. 2019 Oct 17;381(16):1596-1597. doi: 10.1056/NEJMc1910735. No abstract available.

PMID:
31618556
14.

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.

Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V.

Lancet Respir Med. 2020 Feb;8(2):147-157. doi: 10.1016/S2213-2600(19)30341-8. Epub 2019 Sep 29.

PMID:
31578169
15.

Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease.

Distler O, Volkmann ER, Hoffmann-Vold AM, Maher TM.

Expert Rev Clin Immunol. 2019 Oct;15(10):1009-1017. doi: 10.1080/1744666X.2020.1668269. Epub 2019 Sep 30.

16.

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design.

Santermans E, Ford P, Kreuter M, Verbruggen N, Meyvisch P, Wuyts WA, Brown KK, Lederer DJ, Byrne AJ, Molyneaux PL, Sivananthan A, Moor CC, Maher TM, Wijsenbeek M.

Adv Ther. 2019 Nov;36(11):3059-3070. doi: 10.1007/s12325-019-01093-3. Epub 2019 Sep 29.

17.

Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis.

Ng B, Dong J, D'Agostino G, Viswanathan S, Widjaja AA, Lim WW, Ko NSJ, Tan J, Chothani SP, Huang B, Xie C, Pua CJ, Chacko AM, Guimarães-Camboa N, Evans SM, Byrne AJ, Maher TM, Liang J, Jiang D, Noble PW, Schafer S, Cook SA.

Sci Transl Med. 2019 Sep 25;11(511). pii: eaaw1237. doi: 10.1126/scitranslmed.aaw1237.

PMID:
31554736
18.

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.

Maher TM, Strek ME.

Respir Res. 2019 Sep 6;20(1):205. doi: 10.1186/s12931-019-1161-4. Review.

19.

Overlap of Genetic Risk between Interstitial Lung Abnormalities and Idiopathic Pulmonary Fibrosis.

Hobbs BD, Putman RK, Araki T, Nishino M, Gudmundsson G, Gudnason V, Eiriksdottir G, Zilhao Nogueira NR, Dupuis J, Xu H, O'Connor GT, Manichaikul A, Nguyen J, Podolanczuk AJ, Madahar P, Rotter JI, Lederer DJ, Barr RG, Rich SS, Ampleford EJ, Ortega VE, Peters SP, O'Neal WK, Newell JD Jr, Bleecker ER, Meyers DA, Allen RJ, Oldham JM, Ma SF, Noth I, Jenkins RG, Maher TM, Hubbard RB, Wain LV, Fingerlin TE, Schwartz DA, Washko GR, Rosas IO, Silverman EK, Hatabu H, Cho MH, Hunninghake GM.

Am J Respir Crit Care Med. 2019 Dec 1;200(11):1402-1413. doi: 10.1164/rccm.201903-0511OC.

PMID:
31339356
20.

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.

Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Rohr KB, Michael A, Ittrich C, Diefenbach C, Jenkins RG; INMARK trial investigators.

Lancet Respir Med. 2019 Sep;7(9):771-779. doi: 10.1016/S2213-2600(19)30255-3. Epub 2019 Jul 17.

21.

Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort.

Organ LA, Duggan AR, Oballa E, Taggart SC, Simpson JK, Kang'ombe AR, Braybrooke R, Molyneaux PL, North B, Karkera Y, Leeming DJ, Karsdal MA, Nanthakumar CB, Fahy WA, Marshall RP, Jenkins RG, Maher TM.

Respir Res. 2019 Jul 12;20(1):148. doi: 10.1186/s12931-019-1118-7.

22.

Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.

Wollin L, Distler JHW, Redente EF, Riches DWH, Stowasser S, Schlenker-Herceg R, Maher TM, Kolb M.

Eur Respir J. 2019 Sep 19;54(3). pii: 1900161. doi: 10.1183/13993003.00161-2019. Print 2019 Sep. Review.

23.

Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis.

Walsh SLF, Lederer DJ, Ryerson CJ, Kolb M, Maher TM, Nusser R, Poletti V, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown KK, Corte TJ, Cottin V, Crestani B, Flaherty KR, Glaspole IN, Grutters J, Inoue Y, Kondoh Y, Kreuter M, Johannson KA, Ley B, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts WA, Wells AU.

Am J Respir Crit Care Med. 2019 Nov 1;200(9):1146-1153. doi: 10.1164/rccm.201903-0493OC.

24.

King's Brief Interstitial Lung Disease questionnaire: responsiveness and minimum clinically important difference.

Nolan CM, Birring SS, Maddocks M, Maher TM, Patel S, Barker RE, Jones SE, Walsh JA, Wynne SC, George PM, Man WD.

Eur Respir J. 2019 Sep 5;54(3). pii: 1900281. doi: 10.1183/13993003.00281-2019. Print 2019 Sep.

25.

Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis.

Jacob J, Bartholmai BJ, van Moorsel CHM, Rajagopalan S, Devaraj A, van Es HW, Moua T, van Beek FT, Clay R, Veltkamp M, Kokosi M, de Lauretis A, Judge EP, Jacob TM, Peikert T, Karwoski R, Maldonado F, Renzoni E, Maher TM, Altmann A, Wells AU.

Eur Respir J. 2019 Sep 30;54(3). pii: 1802341. doi: 10.1183/13993003.02341-2018. Print 2019 Sep. No abstract available.

26.

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).

Maher TM, Kreuter M, Lederer DJ, Brown KK, Wuyts W, Verbruggen N, Stutvoet S, Fieuw A, Ford P, Abi-Saab W, Wijsenbeek M.

BMJ Open Respir Res. 2019 May 21;6(1):e000422. doi: 10.1136/bmjresp-2019-000422. eCollection 2019.

27.

Variable utility of mosaic attenuation to distinguish fibrotic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis.

Barnett J, Molyneaux PL, Rawal B, Abdullah R, Hare SS, Vancheeswaran R, Desai SR, Maher TM, Wells AU, Devaraj A.

Eur Respir J. 2019 Jul 25;54(1). pii: 1900531. doi: 10.1183/13993003.00531-2019. Print 2019 Jul.

PMID:
31164428
28.

Management of Fibrosing Interstitial Lung Diseases.

Maher TM, Wuyts W.

Adv Ther. 2019 Jul;36(7):1518-1531. doi: 10.1007/s12325-019-00992-9. Epub 2019 May 22. Review.

29.

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators.

N Engl J Med. 2019 Jun 27;380(26):2518-2528. doi: 10.1056/NEJMoa1903076. Epub 2019 May 20.

30.

The Transferrin Receptor CD71 Delineates Functionally Distinct Airway Macrophage Subsets during Idiopathic Pulmonary Fibrosis.

Allden SJ, Ogger PP, Ghai P, McErlean P, Hewitt R, Toshner R, Walker SA, Saunders P, Kingston S, Molyneaux PL, Maher TM, Lloyd CM, Byrne AJ.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):209-219. doi: 10.1164/rccm.201809-1775OC.

31.

Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis.

Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, Lee J, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Kim DS, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundy JS, O'Riordan T, Strek ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, Inoue Y, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, Tomassetti S, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl D, Molina-Molina M, Machahua C, Worboys AM, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Vašáková M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA.

Am J Respir Crit Care Med. 2019 Jul 15;200(2):199-208. doi: 10.1164/rccm.201810-1891OC.

32.

The King's Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference.

Sinha A, Patel AS, Siegert RJ, Bajwah S, Maher TM, Renzoni EA, Wells AU, Higginson IJ, Birring SS.

BMJ Open Respir Res. 2019 Feb 18;6(1):e000363. doi: 10.1136/bmjresp-2018-000363. eCollection 2019.

33.

Sarcoidosis in the UK: insights from British Thoracic Society registry data.

Thillai M, Chang W, Chaudhuri N, Forrest I, Ho LP, Lines S, Maher TM, Spencer LG, Spiteri M, Coker R.

BMJ Open Respir Res. 2019 Feb 18;6(1):e000357. doi: 10.1136/bmjresp-2018-000357. eCollection 2019.

34.

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation.

Maher TM, Lancaster LH, Jouneau S, Morrison L, Lederer DJ, Molina-Molina M, Bendstrup E, Kirchgaessler KU, Gilberg F, Axmann J, Petzinger U, Noble PW.

Ann Am Thorac Soc. 2019 Jul;16(7):927-930. doi: 10.1513/AnnalsATS.201810-720RL. No abstract available.

35.

Can monocytes predict prognosis of idiopathic pulmonary fibrosis?

Kreuter M, Maher TM.

Lancet Respir Med. 2019 Jun;7(6):467-469. doi: 10.1016/S2213-2600(19)30050-5. Epub 2019 Mar 29. No abstract available.

36.

In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia is associated with disease progression and mortality.

Mackintosh JA, Desai SR, Adamali H, Patel K, Chua F, Devaraj A, Kouranos V, Kokosi M, Margaritopoulos G, Renzoni EA, Wells AU, Molyneaux PL, Kumar S, Maher TM, George PM.

Eur Respir J. 2019 May 23;53(5). pii: 1802412. doi: 10.1183/13993003.02412-2018. Print 2019 May. No abstract available.

PMID:
30923184
37.

Idiopathic Pulmonary Fibrosis: New and Emerging Treatment Options.

Hewitt RJ, Maher TM.

Drugs Aging. 2019 Jun;36(6):485-492. doi: 10.1007/s40266-019-00647-y. Review.

PMID:
30864023
38.

Patient-reported distress can aid clinical decision-making in idiopathic pulmonary fibrosis: analysis of the PROFILE cohort.

Stewart I, McKeever T, Braybrooke R, Oballa E, Simpson JK, Maher TM, Marshall RP, Lukey PT, Fahy WA, Jenkins G, Saini G.

Eur Respir J. 2019 May 9;53(5). pii: 1801925. doi: 10.1183/13993003.01925-2018. Print 2019 May.

PMID:
30846471
39.

A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis.

Lukey PT, Harrison SA, Yang S, Man Y, Holman BF, Rashidnasab A, Azzopardi G, Grayer M, Simpson JK, Bareille P, Paul L, Woodcock HV, Toshner R, Saunders P, Molyneaux PL, Thielemans K, Wilson FJ, Mercer PF, Chambers RC, Groves AM, Fahy WA, Marshall RP, Maher TM.

Eur Respir J. 2019 Mar 18;53(3). pii: 1801992. doi: 10.1183/13993003.01992-2018. Print 2019 Mar.

PMID:
30765508
40.

Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis.

Brown KK, Flaherty KR, Cottin V, Raghu G, Inoue Y, Azuma A, Huggins JT, Richeldi L, Stowasser S, Stansen W, Schlenker-Herceg R, Maher TM, Wells AU.

Respir Med. 2019 Jan;146:42-48. doi: 10.1016/j.rmed.2018.11.012. Epub 2018 Nov 19.

41.

Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities.

Fischer A, Strek ME, Cottin V, Dellaripa PF, Bernstein EJ, Brown KK, Danoff SK, Distler O, Hirani N, Jones KD, Khanna D, Lee JS, Lynch DA, Maher TM, Millar AB, Raghu G, Silver RM, Steen VD, Volkmann ER, Mullan RH, O'Dwyer DN, Donnelly SC.

QJM. 2019 Feb 1;112(2):81-93. doi: 10.1093/qjmed/hcy272. No abstract available.

42.

Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities.

Fischer A, Strek ME, Cottin V, Dellaripa PF, Bernstein EJ, Brown KK, Danoff SK, Distler O, Hirani N, Jones KD, Khanna D, Lee JS, Lynch DA, Maher TM, Millar AB, Raghu G, Silver RM, Steen VD, Volkmann ER, Mullan RH, O'Dwyer DN, Donnelly SC.

Arthritis Rheumatol. 2019 Feb;71(2):182-195. doi: 10.1002/art.40769. Epub 2019 Jan 3. No abstract available.

43.

The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis.

Woodcock HV, Eley JD, Guillotin D, Platé M, Nanthakumar CB, Martufi M, Peace S, Joberty G, Poeckel D, Good RB, Taylor AR, Zinn N, Redding M, Forty EJ, Hynds RE, Swanton C, Karsdal M, Maher TM, Bergamini G, Marshall RP, Blanchard AD, Mercer PF, Chambers RC.

Nat Commun. 2019 Jan 2;10(1):6. doi: 10.1038/s41467-018-07858-8.

44.

Gait speed and prognosis in patients with idiopathic pulmonary fibrosis: a prospective cohort study.

Nolan CM, Maddocks M, Maher TM, Banya W, Patel S, Barker RE, Jones SE, George PM, Cullinan P, Man WD.

Eur Respir J. 2019 Feb 7;53(2). pii: 1801186. doi: 10.1183/13993003.01186-2018. Print 2019 Feb.

PMID:
30487200
45.

Predicting outcomes in rheumatoid arthritis related interstitial lung disease.

Jacob J, Hirani N, van Moorsel CHM, Rajagopalan S, Murchison JT, van Es HW, Bartholmai BJ, van Beek FT, Struik MHL, Stewart GA, Kokosi M, Egashira R, Brun AL, Cross G, Barnett J, Devaraj A, Margaritopoulos G, Karwoski R, Renzoni E, Maher TM, Wells AU.

Eur Respir J. 2019 Jan 3;53(1). pii: 1800869. doi: 10.1183/13993003.00869-2018. Print 2019 Jan.

46.

No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone.

Richeldi L, Fletcher S, Adamali H, Chaudhuri N, Wiebe S, Wind S, Hohl K, Baker A, Schlenker-Herceg R, Stowasser S, Maher TM.

Eur Respir J. 2019 Jan 10;53(1). pii: 1801060. doi: 10.1183/13993003.01060-2018. Print 2019 Jan.

PMID:
30442716
47.

The potential impact of azithromycin in idiopathic pulmonary fibrosis.

Macaluso C, Maritano Furcada J, Alzaher O, Chaube R, Chua F, Wells AU, Maher TM, George PM, Renzoni EA, Molyneaux PL.

Eur Respir J. 2019 Feb 14;53(2). pii: 1800628. doi: 10.1183/13993003.00628-2018. Print 2019 Feb. No abstract available.

PMID:
30442715
48.

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study.

Cottin V, Koschel D, Günther A, Albera C, Azuma A, Sköld CM, Tomassetti S, Hormel P, Stauffer JL, Strombom I, Kirchgaessler KU, Maher TM.

ERJ Open Res. 2018 Oct 19;4(4). pii: 00084-2018. doi: 10.1183/23120541.00084-2018. eCollection 2018 Oct.

49.

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.

Fletcher SV, Jones MG, Renzoni EA, Parfrey H, Hoyles RK, Spinks K, Kokosi M, Kwok A, Warburton C, Titmuss V, Thillai M, Simler N, Maher TM, Brereton CJ, Chua F, Wells AU, Richeldi L, Spencer LG.

ERJ Open Res. 2018 Oct 19;4(4). pii: 00049-2018. doi: 10.1183/23120541.00049-2018. eCollection 2018 Oct.

50.

PD-1 up-regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-β1 production.

Celada LJ, Kropski JA, Herazo-Maya JD, Luo W, Creecy A, Abad AT, Chioma OS, Lee G, Hassell NE, Shaginurova GI, Wang Y, Johnson JE, Kerrigan A, Mason WR, Baughman RP, Ayers GD, Bernard GR, Culver DA, Montgomery CG, Maher TM, Molyneaux PL, Noth I, Mutsaers SE, Prele CM, Peebles RS Jr, Newcomb DC, Kaminski N, Blackwell TS, Van Kaer L, Drake WP.

Sci Transl Med. 2018 Sep 26;10(460). pii: eaar8356. doi: 10.1126/scitranslmed.aar8356.

Supplemental Content

Loading ...
Support Center